Insight Molecular Diagnostics Inc. — Director's Dealing 2015

Dec 31, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2015-12-30

Reporting Person: Arno Andrew (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$2.20	2025-06-29	Common Stock (10000)		Direct

Footnotes

F1: Will become exercisable in four equal installments at the end of each calendar quarter based upon continued service on the board of directors from the date of grant.